Composition for inducing proliferation or accumulation of regulatory T cells
It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
1. A method of treating a human subject having an infectious disease, an autoimmune disease or an allergic disease, the method comprising
administering a pharmaceutical composition comprising a purified bacterial mixture of at least four live bacterial strains belonging to Clostridium clusters IV and/or XIVa to the human subject,
wherein the bacterial strains are spore-forming bacteria and are isolated from a human.
2. The method of claim 1 , wherein the pharmaceutical composition comprises five or more bacterial strains.
3. The method of claim 1 , wherein the pharmaceutical composition comprises six or more bacterial strains.
4. The method of claim 1 , wherein the pharmaceutical composition comprises seven or more bacterial strains.
5. The method of claim 1 , wherein the pharmaceutical composition comprises eight or more bacterial strains.
6. The method of claim 1 , wherein the pharmaceutical composition comprises nine or more bacterial strains.
7. The method of claim 1 , wherein the pharmaceutical composition comprises ten or more bacterial strains.
8. The method of claim 1 , wherein the pharmaceutical composition comprises eleven or more bacterial strains.
9. The method of claim 1 , wherein the pharmaceutical composition comprises twelve or more bacterial strains.
10. The method of claim 1 , wherein the pharmaceutical composition comprises thirteen or more bacterial strains.
11. The method of claim 1 , wherein the pharmaceutical composition comprises fourteen or more bacterial strains.
12. The method of claim 1 , wherein the pharmaceutical composition comprises fifteen or more bacterial strains.
13. The method of claim 1 , wherein the human has an autoimmune disease.
14. The method of claim 13 , wherein the autoimmune disease is organ transplant rejection, inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, sprue, rheumatoid arthritis, Type I diabetes, graft versus host disease, or multiple sclerosis.
15. The method of claim 13 , wherein the autoimmune disease is inflammatory bowel disease (IBD).
16. The method of claim 13 , wherein the autoimmune disease is ulcerative colitis.
17. The method of claim 13 , wherein the autoimmune disease is Crohn's disease.
18. The method of claim 1 , wherein the human has an allergic disease.
19. The method of claim 1 , wherein the human has an infectious disease.
20. The method of claim 19 , wherein the infectious disease is Clostridium difficile infection.
21. The method of claim 1 , wherein the pharmaceutical composition is formulated for delivery to the intestine.
22. The method of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.
23. The method of claim 1 , wherein the pharmaceutical composition comprises a pH sensitive composition comprising one or more enteric polymers.
24. The method of claim 1 , wherein the pharmaceutical composition is in the form of a capsule.
25. The method of claim 1 , wherein the bacteria are in the form of spores.
26. A method of treating a human subject having an allergic disease, the method comprising
administering a pharmaceutical composition comprising a purified bacterial mixture of at least two live bacterial strains belonging to Clostridium clusters IV and/or XIVa to the human subject,
wherein the bacterial strains are isolated from a human, and wherein the composition does not include Bacteroides.
27. The method of claim 26 , wherein the pharmaceutical composition is formulated for delivery to the intestine.
28. The method of claim 26 , wherein the pharmaceutical composition is formulated for oral administration.
29. The method of claim 26 , wherein the pharmaceutical composition comprises a pH sensitive composition comprising one or more enteric polymers.
30. The method of claim 26 , wherein the pharmaceutical composition is in the form of a capsule.
31. The method of claim 26 , wherein the bacteria are in the form of spores.
32. A method of treating a human subject having an allergic disease, the method comprising
administering a pharmaceutical composition comprising a purified bacterial mixture of at least two live bacterial strains belonging to Clostridium clusters IV and/or XIVa to the human subject,
wherein the bacterial strains are isolated from a human, and wherein the composition does not include Lactobacillus.
33. The method of claim 32 , wherein the pharmaceutical composition is formulated for delivery to the intestine.
34. The method of claim 32 , wherein the pharmaceutical composition is formulated for oral administration.
35. The method of claim 32 , wherein the pharmaceutical composition comprises a pH sensitive composition comprising one or more enteric polymers.
36. The method of claim 32 , wherein the pharmaceutical composition is in the form of a capsule.
37. The method of claim 32 , wherein the bacteria are in the form of spores.
38. A method of treating a human subject having an allergic disease, the method comprising
administering a pharmaceutical composition comprising a purified bacterial mixture of at least two live bacterial strains belonging to Clostridium clusters IV and/or XIVa to the human subject,
wherein the bacterial strains are isolated from a human, and wherein the composition does not include Bifidobacterium.
39. The method of claim 38 , wherein the pharmaceutical composition is formulated for delivery to the intestine.
40. The method of claim 38 , wherein the pharmaceutical composition is formulated for oral administration.
41. The method of claim 38 , wherein the pharmaceutical composition comprises a pH sensitive composition comprising one or more enteric polymers.
42. The method of claim 38 , wherein the pharmaceutical composition is in the form of a capsule.
43. The method of claim 38 , wherein the bacteria are in the form of spores.